| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
|
N Engl J Med
|
2005
|
14.50
|
|
2
|
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.
|
Genome Biol
|
2012
|
5.66
|
|
3
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
N Engl J Med
|
2013
|
4.75
|
|
4
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
N Engl J Med
|
2012
|
4.41
|
|
5
|
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
|
Gut
|
2012
|
4.24
|
|
6
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
N Engl J Med
|
2013
|
3.98
|
|
7
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
Gastroenterology
|
2009
|
3.73
|
|
8
|
Possible association between isotretinoin and inflammatory bowel disease.
|
Am J Gastroenterol
|
2006
|
2.97
|
|
9
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
Gastroenterology
|
2011
|
2.96
|
|
10
|
Risks and benefits of infliximab for the treatment of Crohn's disease.
|
Clin Gastroenterol Hepatol
|
2006
|
2.88
|
|
11
|
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
|
Clin Gastroenterol Hepatol
|
2009
|
2.72
|
|
12
|
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
|
Gastroenterology
|
2007
|
2.55
|
|
13
|
Development of the Crohn's disease digestive damage score, the Lémann score.
|
Inflamm Bowel Dis
|
2010
|
2.20
|
|
14
|
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
|
Gastroenterology
|
2005
|
2.05
|
|
15
|
LRRK2 is involved in the IFN-gamma response and host response to pathogens.
|
J Immunol
|
2010
|
1.85
|
|
16
|
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
|
Gut
|
2011
|
1.80
|
|
17
|
The risk of developing Crohn's disease after an appendectomy: a meta-analysis.
|
Am J Gastroenterol
|
2008
|
1.74
|
|
18
|
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.
|
Gastroenterology
|
2007
|
1.71
|
|
19
|
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
|
Gastroenterology
|
2007
|
1.60
|
|
20
|
Prevention and treatment of osteoporosis in inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2006
|
1.58
|
|
21
|
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.
|
Gastroenterology
|
2008
|
1.56
|
|
22
|
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.
|
Inflamm Bowel Dis
|
2010
|
1.42
|
|
23
|
Occurrence of colon ischemia in relation to irritable bowel syndrome.
|
Am J Gastroenterol
|
2004
|
1.25
|
|
24
|
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
|
Inflamm Bowel Dis
|
2011
|
1.22
|
|
25
|
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists.
|
J Pediatr Gastroenterol Nutr
|
2009
|
1.22
|
|
26
|
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
|
Am J Gastroenterol
|
2012
|
1.22
|
|
27
|
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease.
|
Am J Gastroenterol
|
2006
|
1.21
|
|
28
|
The inflammatory bowel diseases and ambient air pollution: a novel association.
|
Am J Gastroenterol
|
2010
|
1.19
|
|
29
|
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
|
Inflamm Bowel Dis
|
2010
|
1.15
|
|
30
|
Abatacept for Crohn's disease and ulcerative colitis.
|
Gastroenterology
|
2012
|
1.15
|
|
31
|
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting.
|
Inflamm Bowel Dis
|
2011
|
1.14
|
|
32
|
Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
|
Gastroenterology
|
2013
|
1.14
|
|
33
|
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2008
|
1.13
|
|
34
|
Are adult patients more tolerant of treatment risks than parents of juvenile patients?
|
Risk Anal
|
2008
|
1.13
|
|
35
|
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.
|
J Manag Care Pharm
|
2010
|
1.11
|
|
36
|
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.
|
J Gastrointest Surg
|
2008
|
1.09
|
|
37
|
Risk factors for colorectal cancer in Crohn's colitis: a case-control study.
|
Inflamm Bowel Dis
|
2006
|
1.05
|
|
38
|
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?
|
Inflamm Bowel Dis
|
2012
|
1.00
|
|
39
|
Acute appendicitis following colonoscopy.
|
J Clin Gastroenterol
|
2005
|
1.00
|
|
40
|
Risk factors for colon ischemia.
|
Am J Gastroenterol
|
2004
|
1.00
|
|
41
|
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2006
|
0.99
|
|
42
|
State of the art: IBD therapy and clinical trials in IBD.
|
Inflamm Bowel Dis
|
2005
|
0.98
|
|
43
|
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
|
Gut
|
2011
|
0.97
|
|
44
|
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States.
|
J Clin Gastroenterol
|
2013
|
0.96
|
|
45
|
The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark.
|
Gut
|
2007
|
0.96
|
|
46
|
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.
|
Inflamm Bowel Dis
|
2010
|
0.93
|
|
47
|
Selective leukocyte apheresis for the treatment of inflammatory bowel disease.
|
J Clin Gastroenterol
|
2007
|
0.92
|
|
48
|
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
|
Am J Gastroenterol
|
2003
|
0.92
|
|
49
|
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.
|
Antimicrob Agents Chemother
|
2003
|
0.92
|
|
50
|
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
|
Inflamm Bowel Dis
|
2011
|
0.89
|
|
51
|
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center.
|
J Crohns Colitis
|
2013
|
0.86
|
|
52
|
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.
|
Clin Gastroenterol Hepatol
|
2011
|
0.85
|
|
53
|
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire.
|
Inflamm Bowel Dis
|
2009
|
0.85
|
|
54
|
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
|
Am J Gastroenterol
|
2008
|
0.85
|
|
55
|
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors.
|
Scand J Gastroenterol
|
2015
|
0.84
|
|
56
|
Efficacy of methotrexate in ulcerative colitis: failure or promise.
|
Inflamm Bowel Dis
|
2010
|
0.83
|
|
57
|
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.
|
Inflamm Bowel Dis
|
2014
|
0.83
|
|
58
|
Effects of growth hormone secretion on body composition in patients with Crohn's disease.
|
J Clin Endocrinol Metab
|
2003
|
0.82
|
|
59
|
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?
|
Surgery
|
2011
|
0.81
|
|
60
|
Genetics, Genetic Testing, and Biomarkers of Digestive Diseases.
|
Gastroenterology
|
2015
|
0.80
|
|
61
|
Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study.
|
Inflamm Bowel Dis
|
2015
|
0.80
|
|
62
|
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry.
|
Inflamm Bowel Dis
|
2014
|
0.80
|
|
63
|
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.
|
Inflamm Bowel Dis
|
2013
|
0.80
|
|
64
|
Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial.
|
JMIR Res Protoc
|
2015
|
0.78
|
|
65
|
Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting.
|
Inflamm Bowel Dis
|
2015
|
0.78
|
|
66
|
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.
|
Inflamm Bowel Dis
|
2010
|
0.78
|
|
67
|
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.
|
Inflamm Bowel Dis
|
2017
|
0.78
|
|
68
|
Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians.
|
Med Health R I
|
2012
|
0.77
|
|
69
|
Body image dissatisfaction in patients with inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2015
|
0.77
|
|
70
|
Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis.
|
Inflamm Bowel Dis
|
2014
|
0.77
|
|
71
|
Babesiosis in a patient on infliximab for Crohn's disease.
|
Inflamm Bowel Dis
|
2010
|
0.77
|
|
72
|
Within you, without you: is gastroenterology ready to embrace the "exposome"?
|
Gastroenterology
|
2012
|
0.76
|
|
73
|
Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease.
|
J Med Internet Res
|
2016
|
0.75
|
|
74
|
Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.
|
Inflamm Bowel Dis
|
2016
|
0.75
|
|
75
|
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.
|
Inflamm Bowel Dis
|
2016
|
0.75
|
|
76
|
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.
|
Inflamm Bowel Dis
|
2017
|
0.75
|